Reanalysis of the crystalloid versus hydroxyethyl starch trial (CHEST)

New England Journal of Medicine

Volumn 377, Issue 3, 2017, Pages 298-300

  Patel, Anushka ^a   Pieper, Karen ^b   Myburgh, John A ^a   Perkovic, Vlado ^a   Finfer, Simon ^a   Yang, Qinghong ^b   Li, Qiang ^a   Billot, Laurent ^a  

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH; SODIUM CHLORIDE; HETASTARCH DERIVATIVE; ISOTONIC SOLUTION;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; COMPARATIVE STUDY; CRITICALLY ILL PATIENT; CRYSTALLOID; DRUG SAFETY; FLUID RESUSCITATION; HUMAN; LETTER; MOLECULAR WEIGHT; MORTALITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; FLUID THERAPY;

FLUID THERAPY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; ISOTONIC SOLUTIONS;

EID: 85025457714     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1703337     Document Type: Letter

References (4)

1. Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012;367:1901-11.
2. Mutter TC, Ruth CA, Dart AB. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2013;7:CD007594.
3. Crystalloid versus Hydroxyethyl Starch Trial (CHEST) Management Committee. The Crystalloid versus Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality. Intensive Care Med 2011;37:816-23.
4. ICH Harmonised tripartite guideline: statistical principles for clinical trials E9. February 1998 (http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9 _Guideline.pdf).